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Abstract
Purpose To estimate quality-adjusted life years (QALY)
loss due to each of the following nine chronic conditions—
depression, diabetes mellitus, hypertension, heart disease,
stroke, emphysema, asthma, arthritis, and cancer.
Methods We ascertained respondents’ health-related
quality of life scores and mortality status from the 2005 to
2008 National Health and Nutrition Examination Survey
(NHANES) with mortality follow-up data through
December 31, 2011. We included respondents aged
65 years and older (n = 2380). A hybrid estimator was
used to calculate QALY from two parts: QALY during the
follow-up period and QALY beyond the follow-up period.
We calculated QALY by each of the nine chronic
conditions.
Results For persons aged 65 and older, QALY throughout
the reminder of lifetime was 12.3 years. After adjusting for
age- and sex-related differences, depression had an asso-
ciated 8.2 years of QALY loss; diabetes, 5.6 years;
hypertension, 2.5 years; heart disease, 5.4 years; stroke,
6.4 years; emphysema, 8.0 years; asthma, 4.8 years;
arthritis, 0.3 years; and cancer, 2.5 years. Compared to
persons without any chronic conditions, persons with one
condition had an associated 4.7 years of QALY loss;
persons with two conditions, 7.9 years; and persons with
three or more conditions, 10.8 years.
Conclusions This study presents a QALY estimator for
respondents in the NHANES-Linked Mortality File and
demonstrates the utility of this method to other follow-up
data. Continued application of our method would enable
the burden of disease to be compared for a range of health
conditions and risk factors in the ongoing effort to improve
population health.
Keywords Quality-adjusted life year (QALY)  Health-
related quality of life (HRQOL)  Chronic conditions 
Burden of disease
Introduction
The health impact of many chronic conditions and risk
factors includes both fatal and nonfatal outcomes [1]. For
example, diabetes mellitus has been associated with
increased mortality [2] and increased risk of disability or
deteriorating health-related quality of life (HRQOL) [3]. It
would be particularly useful to quantify the lifetime overall
burden of a disease or a risk factor in a single value index
that reflects all aspects of health, including nonfatal illness
and mortality outcomes [4, 5]. Such analyses will make it
possible to enable the direct comparison of the overall
burden attributed to different diseases and risk factors [5,
6]. Several indices have been developed and used for this
purpose [7–9]. One of the most widely used indices is
disability-adjusted life years (DALY) [8]. It is calculated as
the sum of year of life lost (YLL) and years lived in dis-
ability (YLD), so this method treats losses to mortality and
to morbidity equally and treats the losses at different ages
equally. Another widely used index is disability-free life
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expectancy (DFLE), which is a modification of life
expectancy [9]. In a period life table, which is commonly
used to calculate life expectancy, the number of life years
in an age interval for a stationary population cohort is
multiplied by the proportion of persons in that age interval
who are free of disability. Therefore, DFLE calculation
relies on the life table method’s stationarity assumption
that the age-specific hazard rate (i.e., probability of dying
in each age interval) is constant over time [10].
Quality-adjusted life years (QALY) is a health outcome
measure that weights life years lived with preference-based
health-related quality of life (HRQOL) scores [7]. Prefer-
ence-based HRQOL, also called health utility value, is a
summary score that assesses the values of one health state
vs. another state. The health utility value is anchored at 0
for death and 1 for perfect health [11], so 1 year lived in a
reduced health state of utility value of 0.5 is equal to 0.5
QALYs, the same as lived one half year in perfect health.
The mean QALY throughout the remainder of the lifetime




q tð ÞS tð Þdt;
where q(t) is the HRQOL score at time t and S(t) is the
proportion surviving to time t. The proportion of the pop-
ulation at the start of the cohort is assumed to be 1 (i.e.,
S 0ð Þ ¼ 1).
Because QALY uses the health utility value to weight
years of life lived, one of the advantages of QALY over
DALY and DFLE is that it can be used for calculating the
economic costs of a condition or a risk factor and for
analyzing the cost-effectiveness of alternative treatments,
intervention programs, and health policies [5, 6, 12].
However, calculation of mean QALY can be difficult due
to censoring [13, 14]. It requires extrapolating quality-ad-
justed survival time beyond the time of the last death
occurred [15]. Many investigators instead have calculated
mean QALYs to a chosen time point, such the end of the
study [13, 14]. Because the follow-up time of longitudinal
data is typically short and most participants do not die
during the follow-up, this method does not measure the
lifetime health outcome.
Many studies have estimated the impact of some chronic
diseases and risk factors on the mean QALY starting from
a given age to the remainder of the lifetime for a group of
similarly aged persons, called quality-adjusted life expec-
tancy (QALE) [12, 16–18]. By combining the period life
table and age-specific HRQOL score, the calculation of
QALE is similar to the calculation of DFLE. The number
of life years in each age interval for a stationary population
cohort in a life table is multiplied by the average HRQOL
in that age interval [12]. The main advantage of this
method is its ability to use cross-sectional data because it
uses estimates of mortality rates and mean HRQOL scores
for each age interval [12, 16–18]. However, obtaining
robust and unbiased estimates of mortality rates for the
target population (such as diseased persons) is difficult
since the validity and reliability of these estimates depend
on the data used for estimation and model assumptions [17,
18]. Additionally, this method requires a much larger
sample size to obtain acceptable precision of estimation,
usually tens of thousands [16–18]. Therefore, this method
cannot be used for the calculation of burden of disease for
many chronic conditions and risk factors due to these
limitations.
It is more common to compare participants’ QALY
between the intervention group and the control group in a
randomized controlled trial or between the diseased per-
sons and the nondiseased persons in a population-based
cohort [19–21]. These comparisons of QALY are between
two groups of participants of different ages and probably of
different sociodemographic characteristics and comorbidi-
ties. Therefore, mean QALY cannot be calculated using the
same life table method for the calculation of QALE.
The main goals of the current study are to introduce a
new estimator for QALY during the remainder of lifetime
and to demonstrate the utility of this method by estimating
the impact on QALY for nine chronic conditions for US
adults aged 65 years and older. Six of these nine conditions
were chosen on the basis of their inclusion in other national
data sets (i.e., depression, diabetes mellitus, hypertension,
heart disease, stroke, and asthma) while the other three
conditions were chosen on the basis of prevalence among
the elderly (arthritis) [22], being a leading cause of death in
the USA (cancer) [23] and having a high mortality rate
(emphysema) [24]. We also estimated the impact on age-
adjusted HRQOL score and mortality rate for each of the
nine conditions.
Materials and methods
We ascertained respondents’ HRQOL scores and mortality
status from the 2005 to 2008 http://www.cdc.gov/nchs/
nhanes.htm National Health and Nutrition Examination
Survey (NHANES)-Linked Mortality File [25, 26]. The
NHANES is an ongoing survey of random samples from
the noninstitutionalized civilian population of the USA to
obtain national statistics on health and nutritional status
[25]. With the use of the design weight and adjustment for
noncoverage and nonresponse, the distribution of respon-
dents was representative of that of the US general popu-
lation [25]. The NHANES-Linked Mortality File was
created by the National Center for Health Statistics
(NCHS) by linking the NHANES respondents to the
1922 Qual Life Res (2016) 25:1921–1929
123
National Death Index (NDI) [26]. The respondents in this
analysis had mortality follow-up through December 31,
2011. We included only respondents aged 65 years and
older, yielding a total sample size of 2380.
The NHANES included a questionnaire which asks
respondents to rank their general health from 1 (excellent)
to 5 (poor) and to report numbers of their physically
unhealthy days, mentally unhealthy days, and days with
activity limitation during the past 30 days [27]. This study
employs a previously published mapping algorithm based
on respondents’ age and answers to these four questions to
obtain values of a frequently used preference-based
HRQOL measurement, the EQ-5D index, to calculate
QALY [28]. This algorithm provides valid estimates of
EQ-5D scores for respondents, and the bias of estimated
QALY from these scores has been estimated to be\1 % of
that using the actual EQ-5D questions [29].
The NHANES asked respondents whether or not they had
ever been told they had diabetes mellitus, hypertension,
asthma, arthritis, heart disease (coronary heart disease,
angina, or heart attack), stroke, emphysema, and cancer of
any kind by a doctor or other health professional [25].
Women who had diabetes only during pregnancy were
excluded. Only persons who reported still having asthma at
the time of survey were considered having asthma. Cancer
patients who only reported having skin cancer were exclu-
ded. Participants’ depression status was ascertained from
eight-item Patient Health Questionnaire (PHQ-8) depression
scale [30]. Current depression is defined as PHQ-8 index
C10 [30].
Statistical analysis
Mean QALY throughout the remainder of the lifetime was
estimated with a hybrid method which calculated QALY
from two parts: QALY during the follow-up period (to
December 31, 2011) and QALY beyond the follow-up
period (after December 31, 2011).
The QALY during the follow-up period was estimated
based on the method by Shen et al. [14]. Let L be the time of
the end of follow-up and 0\ t1 B t2 B  B tl\L be times
when deaths occurred. Suppose S^KMðtÞ is the Kaplan–Meier
estimated survival function. We calculate mean QALY at
tiði ¼ 1; . . .; lÞ, Q^ðtiÞ, for those who died at ti; and at time L,
Q^ðLÞ, for those who were alive at the end of follow-up.






  S^KM tj  
" #
þ Q^ Lð ÞS^KM tlð Þ;
where t0 = 0 and S(t0) = S(0) = 1.
QALY beyond the follow-up period was estimated by
extrapolating survival function S(t) beyond time L.
However, because the model usually fits data well during
the early follow-up but does not fit data well near the end
of the follow-up, the model may not extrapolate the sur-
vival function well in the tail [15]. Instead, we used the
parametric method to estimate total expected life years and
the Kaplan–Meier method to estimate life years from time
0 to L. We used Weibull model, SpðtÞ ¼ exp½ðt=kÞb and
the QALYs in the tail was estimated as:






S^KM tið Þ tiþ1  tið Þ
" #
þ S^KM tkð Þ L tkð Þ
( ))
;
where CðÞ is the gamma function. We used the mean EQ-
5D index at time L, q(L), for HRQOL estimates beyond the
end of follow-up because extrapolation of q(t) outside the
data range is usually unreliable.
The QALY loss due to a chronic disease was defined as
the difference in QALY for those without the disease and
those with the disease [18]. We used a propensity score
method to account for the systematic difference in partic-
ipants’ characteristics, such as age and sex, between the
diseased and nondisease individuals [31]. This was done by
using the inverse probability of selection weight to create a
weighted sample in which the distribution of participants’
characteristics was independent of disease status.
Results
The average age of the participants was 73.6 years
(SD = 5.8 years) at the start of the study (Table 1).
Women comprised 56.1 % of the population and white
non-Hispanics comprised 84.0 % of the population. Only
8.2 % of participants were black non-Hispanics and 5.5 %
were Hispanics. In this population, the mean EQ-5D index
was 0.826 (Table 2). About 17.2 % of participants died
during the follow-up, yielding a mortality rate of 3.83
deaths per 100 person-years. The mean QALY throughout
the remainder of the lifetime was 13.7 years (Table 3).
Compared to men, women had a better age-adjusted mor-
tality rate (3.10 vs. 4.80) but a worse age-adjusted EQ-5D
score (0.807 vs. 0.851). Overall, QALY was significantly
higher among women than among men (15.9 vs.
11.5 years) after adjusting for the difference in age
between men and women.
Loss due to depression
For those aged 65 years and older, 3.8 % persons were
currently depressed (Table 1). Among those with
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depression, the age- and sex-adjusted EQ-5D index was
0.440, 0.405 points lower than those without depression
(Table 2). Such a 0.405-point decrease represented a
decrease of nearly half (47.9 %) the EQ-5D index score
and was at least 5.4 times as much as the 0.025–0.075 point
decrease for each of the other eight conditions. Depression
also had a large impact on mortality rates. The age- and
sex-adjusted mortality rate was 6.77 deaths per 100 person-
years among depressed persons, 3.20 points higher (89.6 %
higher) than that among persons without depression (3.57
deaths per 100 person-years). The mean QALY throughout
the remainder of lifespan for those with depression was 4.6,
9.4 years less than those without depression (14.1 years)
(Table 3). This represented a loss of more than two-thirds
(67.1 %) of QALY due to depression.
The large and significant QALY loss due to depression
occurred for both men (7.6-year loss) and women (10.7-
year loss) and for white non-Hispanics (9.6-year loss)
(Fig. 1). The QALY losses for black non-Hispanics and for
Hispanics were smaller (4.2- and 2.0-year loss, respec-
tively) and not statistically significant. Women lost more
QALY to depression than men did, but men lost a slightly
larger percentage of QALY than women did (65.6 vs.
64.3 %) because men had fewer QALYs. The difference in
QALY loss between men and women was not statistically
significant.
Loss due to diabetes mellitus
Nearly one in five (18.2 %) participants reported that they
had ever been told that they had diabetes by a doctor or other
health professional. Diabetes had a relatively large impact on
mortality and a small impact on HRQOL: 2.32-point increase
(67.8 %) in mortality rate and 0.046-point decrease (5.5 %)
in the EQ-5D index. The total health loss due to diabetes was
large with a loss of 6.3 years in QALY or a loss of 41.2 %
QALY. Such diabetes-associated QALY loss occurred in all
sex and race/ethnicity subgroups. Women with diabetes lost
more QALY (8.6-year loss) than men with diabetes did (4.5-
year loss) and Hispanics lost more QALY (7.4-year loss)
than the other two race/ethnicity subgroups, but these dif-
ferences were not statistically significant.
Loss due to hypertension, heart disease, or stroke
In this population, about three in five (59.7 %) participants
had hypertension, one in five (22.5 %) had heart disease,
and one in ten (10.4 %) had a stroke. The health losses due
to hypertension were small for both fatal and nonfatal
outcomes. Overall, the impact of hypertension on QALY
was small (2.1-year loss) and not statistically significant.
Heart disease had a large impact on mortality and a
relatively small impact on HRQOL. Participants with heart
disease had a mortality rate that was 2.56-points higher
(77.6 %) and an EQ-5D index that was 0.047-points lower
(8.7 %) than participants without heart disease. The total
health loss for heart disease was large, with a 6.5-year loss
(40.7 %) in QALY. This loss occurred for women (10.7-
year loss), white non-Hispanics (7.3-year loss), and black
non-Hispanics (6.5-year loss) only. Although elderly men
were much more likely to have heart disease than elderly
women (29.8 vs. 16.7 %), men with heart disease lost only
2.3 QALYs and such a loss was not statistically significant.
Compared to those who did not have a stroke, persons who
reported having had a stroke had a much higher mortality rate
(4.48-point or 131 % higher) and a lower EQ-5D index
Table 1 Distributions of sample characteristics, 2005–2008
NHANES
N %a SEb (%)
Age: mean ± SD 2380 73.6 ± 5.8
Age groups
65–69 523 30.2 1.5
70–74 503 24.2 1.4
75–79 391 19.6 1.0
80–85 511 21.0 1.5
85? 116 5.0 0.7
Women 1169 56.1 1.0
Race
White non-Hispanics 1521 84.0 2.0
Black non-Hispanics 424 8.2 1.2
Hispanics 385 5.5 0.9
Other 50 2.4 0.6
Died during follow-up 453 17.2 1.2
Depression 98 3.8 0.5
Diabetes 501 18.2 1.0
Hypertension 1423 59.7 1.1
Heart diseasec 532 22.5 1.2
Stroke 255 10.4 1.0
Emphysema 140 6.2 0.7
Asthma 175 7.5 0.7
Arthritis 1268 55.5 1.0
Cancerd 401 17.6 1.0
Conditions: mean ± SD 2380 2.0 ± 1.3
No. of conditions
0 301 12.2 0.7
1 613 26.1 1.2
2 671 28.6 1.0
3? 795 33.1 1.4
a Weighted percentage, accounted for sampling design, noncoverage,
and nonresponse
b Standard error
c Coronary heart disease, angina, or heart attack
d Any kind of cancer, excluding skin cancer
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(0.075-point or 8.7 % lower). Overall, stroke was associated
with more than half (52.6 %) of the QALY loss or a loss of
7.8 years in QALY. Such a large stroke-associated QALY
loss also occurred for both men (5.6-year loss) and women
(9.8-year loss) and for white non-Hispanics (8.6-year loss)
and black non-Hispanics (5.4-year loss).
Loss due to emphysema or asthma
In this population, 6.2 % of participants had emphysema
and 7.5 % of participants reported that they had asthma at
the time of their interview. Emphysema had both a large
impact on a participant’s mortality and HRQOL. The
mortality rate, adjusted by age and sex, among those with
emphysema was about threefold of that among those
without emphysema (10.55 vs. 3.42). The EQ-5D index
among participants with emphysema was 8.9 % lower than
that among participants without emphysema (0.758 vs.
0.832). Overall, emphysema had a very large impact on
QALY with a loss of 9.5 years (64.2 %) in QALY and this
9.5-year loss was the most of the nine diseases examined.
The QALY loss to emphysema occurred for both men (7.8-
Table 2 Mortality rates and
EQ-5D scores by disease status
Conditions N Mortalitya SEb Increase SE EQ-5Dc SE Decrease SE
Total 2380 3.83 0.21 0.826 0.006
Depression
No 2178 3.57 0.32 0.846 0.008
Yes 98 6.77 0.29 3.20 0.43 0.440 0.009 0.405 0.012
Diabetes
No 1875 3.42 0.22 0.834 0.007
Yes 501 5.74 0.54 2.32 0.58 0.788 0.013 0.046 0.015
Hypertension
No 952 3.58 0.22 0.856 0.006
Yes 1423 3.95 0.96 0.37 0.98 0.809 0.023 0.047 0.024
Heart diseased
No 1830 3.30 0.22 0.840 0.006
Yes 532 5.86 1.70 2.56 1.71 0.767 0.039 0.073 0.040
Stroke
No 2115 3.42 0.56 0.835 0.013
Yes 255 7.90 0.22 4.48 0.60 0.760 0.007 0.075 0.015
Emphysema
No 2232 3.42 0.29 0.832 0.008
Yes 140 10.55 0.28 7.13 0.40 0.758 0.008 0.074 0.011
Asthma
No 2194 3.66 0.22 0.833 0.007
Yes 175 5.69 0.67 2.03 0.71 0.760 0.017 0.073 0.018
Arthritis
No 1107 3.89 0.22 0.854 0.006
Yes 1268 3.74 0.47 0.15 0.52 0.806 0.013 0.048 0.015
Cancere
No 1977 3.61 0.56 0.831 0.013
Yes 401 5.21 0.31 1.60 0.64 0.805 0.010 0.025 0.016
No. of conditions
0 301 3.42 0.33 0.884 0.010
1 613 2.66 0.47 0.76 0.57 0.859 0.013 0.025 0.017
2 671 3.14 0.21 0.28 0.39 0.853 0.006 0.031 0.012
3? 795 5.60 1.74 2.18 1.77 0.751 0.032 0.133 0.034
a Mortality rate per 100 person-years of follow-up, adjusted by age and sex in subgroups
b Standard error
c EQ5D index, adjusted by age and sex in subgroups
d Coronary heart disease, angina, or heart attack
e Any kind of cancer, excluding skin cancer
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year loss) and women (10.6-year loss) and for white non-
Hispanics (10.0-year loss) and black non-Hispanics (6.4-
year loss). The loss for Hispanics was also large (7.3-year
loss), but it was not statistically significant, probably due to
small sample size (n = 10).
Asthma had a large impact on mortality but a relatively
smaller impact on HRQOL: a 2.38-point increase (71.7 %)
in mortality rate and a 0.080-point decrease (9.6 %) in EQ-
5D index. Overall, asthma was associated with a relatively
large amount to the QALY loss, with a loss of 4.8 years
(37.2 %). In subgroups, the loss was statistically significant
for men only (4.9-year loss).
Loss due to arthritis
More than half (55.5 %) participants had arthritis. How-
ever, the health impact of arthritis was very small for both
mortality and HRQOL. The QALY was nearly the same for
those with arthritis and for those without arthritis (13.5 vs.
13.9 years).
Loss due to cancer
About 17.6 % of participants reported having cancer.
Compared those without cancer, participants with cancer
had a relatively large increased mortality rate, an increase
of 1.69 points (44.3 %). However, their EQ-5D index was
nearly the same (0.805 vs. 0.831). Overall, the QALY loss
due to cancer was 3.6 years and such a loss was statistically
significant. In subgroups, only women (7.1-year loss) and
white non-Hispanics (3.9-year loss) had a statistically sig-
nificant QALY loss due to cancer.
Loss due to number of chronic conditions
Participants had an average of 2.0 chronic conditions
(SD = 1.3). Nearly nine in ten (87.8 %) participants had at
least one chronic condition, and about one-third (33.1 %)
had at least three chronic conditions. Compared to those
without any of the nine chronic conditions, participants
with one condition had an associated loss of 5.5 years in
QALY; those with two conditions, a loss of 9.2 years in
QALY; and those with three or more conditions, a loss of
12.6 years in QALY.
Discussion
This study estimated mean QALY throughout the remain-
der of the lifetime for participants aged 65 and older from
the NHANES-Linked Mortality File for nine chronic con-
ditions. This method estimates mean QALY based on each
participant’s observed HRQOL score, mortality status, and
follow-up time and, therefore, differs from the life
table method which uses the ‘‘group average’’ of mortality
rates and HRQOL scores in different age intervals [12, 18].
This method has several advantages over previous meth-
ods. First, it does not rely on mortality estimates for the
target population and so allows for the calculation of
QALY loss for any diseases and risk factors included in the
NHANES. Second, it can account for the strong association
Table 3 Quality-adjusted life years (QALY) by diseases status and
QALY loss due to each disease
Diseases QALYa SEb Lossc SE % Loss
Total 13.7 1.3 – – –
Depression
No 14.1 1.5
Yes 4.6 1.5 9.4 1.4 67.1
Diabetes
No 15.3 1.5
Yes 9.0 1.4 6.3 1.4 41.2
Hypertension
No 15.5 1.4
Yes 13.4 1.7 2.1 1.8 13.3
Heart diseased
No 16.0 1.4
Yes 9.5 1.2 6.5 1.6 40.7
Stroke
No 14.8 3.2
Yes 7.0 1.3 7.8 2.9 52.6
Emphysema
No 14.8 2.4
Yes 5.3 1.1 9.5 2.9 64.2
Asthma
No 14.2 1.5
Yes 9.6 1.4 4.6 1.6 32.3
Arthritis
No 13.9 2.0
Yes 13.5 0.9 0.4 3.1 3.1
Cancere
No 14.4 3.8
Yes 10.7 2.2 3.6 1.8 25.4
No. of conditions
0 22.9 1.4
1 17.4 1.0 5.5 3.0 23.8
2 13.7 1.5 9.2 3.7 40.3
3? 10.3 0.8 12.6 1.5 55.1
a Mean QALY throughout the remainder of the lifetime, adjusted for
age and sex for subgroups
b Standard error
c Loss in QALY throughout the remainder of the lifetime
d Coronary heart disease, angina, or heart attack
e Any kind of cancer, excluding skin cancer
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between HRQOL and survival time at the individual level
for the variance estimation, and, therefore, this method
requires smaller sample sizes. Our analyses showed that
QALY estimates were relatively robust even with a small
sample size of approximately 100. Third, it can account for
differences in participants’ characteristics between the
different subgroups, and, as a result, can adjust for any
confounding variables for the comparison of mean QALY
between diseased and nondiseased persons.
In this study, depression and emphysema were associ-
ated with the most overall health losses for US elderly with
more than 60 % losses in QALY, followed by stroke which
was associated with more than 50 % QALY loss. Diabetes
and heart disease were associated with approximately 40 %
QALY losses. Asthma was associated with a little over
30 % QALY loss, and cancer was associated with about
25 % QALY loss. Finally, hypertension had a small health
loss with just a 12 % loss in QALY and arthritis had a
negligible QALY loss with a loss of QALY by only 3.1 %.
In general, these findings were consistent with our under-
standing of these diseases and with findings of DALY for
these conditions from the Global Burden of Disease Study
[8, 32] and QALE loss due to selected chronic conditions
calculated based on the life table method [17, 18, 33].
However, in this study, cancer was associated with only 3.6
QALY loss, a magnitude smaller than the losses to the fol-
lowing six conditions: depression, emphysema, stroke, heart
disease, diabetes, and asthma. This loss was smaller than the
previously estimated health losses due to cancer [8]. For
example, the Global Burden of Disease Study found that
cancer was associated with significantly more DALY than the
other six conditions [8]. There are at least three explanations
for our different results. First, the DALY for cancer was cal-
culated for all ages, so many DALYs were associated with
younger persons with faster growing cancers. For persons
aged 65 years and older, the most common type of cancer is
prostate cancer for men and breast cancer for women, both of
which have higher survival rates [34]. Second, because of
current cancer screening guidelines and terminology, prostate
and breast cancer, as well as other cancers such as thyroid
cancer, may be subject to overdiagnosis and overtreatment
[35]. Third, many participants in this study who reported
cancer had lived with cancer for many years. Specifically, the
average number of years since been told of having cancer was
11.9 years and 67 % of participants with cancer reported
having cancer for five or more years. Therefore, many cancer
patients in this study were cancer survivors and some of them
were ‘‘free of’’ cancer at the time of the interview.
WNH: white non-Hispanics
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Fig. 1 QALY loss due to each disease, overall, by sex, and by race/ethnicity
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Diseases with approximately the same number of QALY
loss may have different losses to fatal and nonfatal out-
comes. For example, depression and emphysema had
nearly the same QALY loss. Depression lost a much larger
proportion of QALY to poor HRQOL score while
emphysema lost a much larger portion of QALY to high
mortality. Emphysema has been associated with a higher
mortality rate [36] while depression has been demonstrated
to have a marked impact on morbidity [37].
We calculated QALY loss due to each of nine selected
chronic diseases as the decrease in QALY for those with
the disease as compared to those without the disease. Of
note, participants without a certain disease might have
other diseases. For example, in our data, among partici-
pants without depression, 87.3 % had at least one of the
other eight diseases. Also, having one disease might be
associated with an increased risk of having some other
diseases [38]. Depression has been associated with an
increased risk of heart disease [39], and, for this sample,
the odds ratio was 2.1. One of the solutions for this prob-
lem is to calculate QALY loss due to a disease by adjusting
for the number of other diseases. After adjusting for the
difference in the number of other diseases as well as age
and sex, the QALY loss due to asthma decreased from 4.6
to 3.1 years. For the other eight conditions, the QALY
losses were mostly unchanged and still in a similar rank
order of QALY loss as the QALY not adjusted by the
number of comorbid conditions.
There were several weaknesses for this study. First,
respondents reported their own disease status, which was
not validated by medical chart reviews. However, the
likelihood is small that respondents would report having a
disease that they did not have, as opposed to omitting to
note having been diagnosed with a given disease. More-
over, because persons who have diabetes or hypertension
may not be aware of having this condition, this study may
have underestimated the disease prevalence and thus the
losses in QALY due to these diseases. Second, the PHQ-8
is not a clinical diagnostic tool for diagnosing depression,
but has been used primarily as a screening instrument for
estimating the prevalence of depression in the general
population. Third, the NHANES did not include the pref-
erence-based HRQOL questions. We used a mapping
algorithm to obtain EQ-5D index scores for respondents
based their answers to the four healthy days questions.
Therefore, estimates of QALY loss would also likely be
underestimated due to regression toward the mean [18].
However, a previous study examined the bias of QALE
estimates and showed that these underestimations were
about 2.5 % for QALE loss [18]. Fourth, this method
requires a sufficient number of deaths during the follow-up
in order to obtain a reliable estimation of QALY. There-
fore, this method cannot provide a reliable QALY
estimation for a younger population or groups with lower
mortality unless the follow-up period is sufficiently long.
This study presents a novel method to estimate the
burden of disease for persons affected by each of nine
common chronic conditions as well as the impact of having
one or more conditions by calculating mean QALYs
throughout the remainder of the lifetime. QALY encom-
passes both years of life lost and relative severity of the
disease and can be used to ascertain the cost-effectiveness
of alternative opportunities to reduce the health burden of a
risk factor or particular disease [5, 6]. While the method is
novel, it has the potential to provide estimates of the bur-
den of diseases for a wide range of risk factors and chronic
health conditions in target populations (i.e., elderly or
‘‘high-risk’’ subgroups) in order to improve population
health. The method developed here may also be applied to
a randomized controlled trial to compare lifetime health
outcomes between treatment and control groups. These
analyses might help inform clinical practice and guide
community health promotion efforts relating to the poten-
tial impact of risk factors and conditions on a given person
as well as population subgroups. In particular, this method
can be used to estimate the contributions of specific dis-
eases to socioeconomic disparities in QALY. Future
research should focus on the relationship between clusters
of conditions and associated behavioral risk factors and
QALY loss as well as the application of these methods to
other data sets which contain more detailed information
pertaining to the diagnosis of clinical conditions.
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